68Ga-FAPI PET与18F-FDG PET诊断原发性肝肿瘤的前瞻性初步研究比较
该前瞻性初步研究纳入20例疑似肝内病变患者,比较68Ga-FAPI PET与18F-FDG PET对原发性肝肿瘤的显像性能。视觉分析显示68Ga-FAPI PET灵敏度100%、特异度100%,18F-FDG PET灵敏度58.8%、特异度100%;68Ga-FAPI PET在肝细胞癌和肝内胆管癌的原发灶SUVmax及靶本比均显著高于18F-FDG PET。
要点
- 68Ga-FAPI PET对原发性肝恶性肿瘤视觉分析灵敏度100%、特异度100%。
- 18F-FDG PET视觉分析灵敏度58.8%、特异度100%。
- 68Ga-FAPI PET/CT在2例ICC患者中识别17处肝外转移,18F-FDG PET/CT识别13处。
核心结论
- 68Ga-FAPI PET-CT在检测原发性肝恶性肿瘤方面较18F-FDG具有更优潜力。
研究设计与样本
- 前瞻性初步研究,纳入20例疑似肝内病变患者,以肿瘤影像学特征、病理或随访检查为参考标准,并与PET扫描结果进行关联分析。
主要发现
- 视觉分析中17例患者68Ga-FAPI摄取增高(灵敏度100%,特异度100%),7例患者18F-FDG摄取增高(灵敏度58.8%,特异度100%)。
- 68Ga-FAPI PET/CT在2例ICC患者中识别17处肝外转移,18F-FDG PET/CT识别13处。
- 3例患者的3个良性肝结节在双PET扫描中摄取可忽略。
- 68Ga-FAPI-04 PET/CT中HCC的SUVmax为8.47±4.06、TBRmax为7.13±5.52,ICC的SUVmax为14.14±2.20、TBRmax为26.46±4.94,均显著高于18F-FDG摄取(HCC SUVmax 4.86±3.58、TBRmax 2.39±2.21;ICC SUVmax 9.19±3.60、TBRmax 2.39±2.21;所有p值<0.05)。
- ICC患者原发肝病灶的FAPI摄取高于肝外转移灶,TBRmax为15.18±5.80(p=0.04)。
关键数值与推荐
- 原发性肝内肿瘤包括14例患者中的16个HCC和3例患者中的4个ICC伴肝外转移,由组织学(n=14)和临床检查(n=3)确定。
- FAPI表达通过免疫组化评估7例HCC/ICC或肉芽肿患者的样本。
临床怎么用
- 对于疑似原发性肝恶性肿瘤的患者,68Ga-FAPI PET-CT在视觉检出和半定量摄取方面均优于18F-FDG PET,可考虑用于提高原发灶及肝外转移的检出。
局限性
- 本研究为初步研究,样本量较小(20例患者),结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to compare the performance of 68Ga-labelled fibroblast activating protein inhibitor (FAPI) PET and 18F-FDG PET for imaging of hepatic tumours. METHODS: We prospectively assessed 20 patients with suspected intrahepatic lesions. Tumour radiological features, pathology, or follow-up examinations were assessed as ground truth in correlation with PET scans. Semiquantitative analysis was additionally performed by measuring the standardised uptake value (SUV). Tumour-to-liver background ratios (TBR) were calculated and compared between 68Ga-FAPI PET and 18F-FDG PET. FAPI expression was assessed by immunochemistry in samples obtained from 7 patients with hepatocellular carcinomas (HCC)/intrahepatic cholangiocarcinoma (ICC) or granulomas. RESULTS: Primary intrahepatic tumours, including 16 HCC in 14 patients and 4 ICC in 3 patients with extrahepatic metastases, were determined by histology (n = 14) and clinical examinations (n = 3). Based on visual analysis, 17 patients presented elevated 68Ga-FAPI uptake (sensitivity: 100%, specificity: 100%), while 7 patients presented 18F-FDG avid tumours (sensitivity: 58.8%, specificity: 100%). 68Ga-FAPI PET/CT identified 17 extrahepatic metastases vs. 13 in 18F-FDG PET/CT in 2 ICC patients. Three benign liver nodules in three patients showed negligible uptake in dual-PET scans. The SUVmax_HCC = 8.47 ± 4.06 and TBRmax_HCC = 7.13 ± 5.52, and SUVmax_ICC = 14.14 ± 2.20 TBRmax_ICC = 26.46 ± 4.94 in 68Ga-FAPI-04 PET/CT were significantly higher than the 18F-FDG uptake presenting SUVmax_HCC = 4.86 ± 3.58 and TBRmax_HCC = 2.39 ± 2.21, and SUVmax_ICC = 9.19 ± 3.60 and TBRmax_ICC = 2.39 ± 2.21 (all p values < 0.05). ICC patients showed higher levels of FAPI uptake in the primary hepatic lesions compared to extrahepatic metastases, TBRmax_ICC = 15.18 ± 5.80 (p = 0.04). CONCLUSIONS: 68Ga-FAPI PET-CT has superior potential in the detection of primary hepatic malignancy compared to 18F-FDG.
引用
- Shi X, Xing H, Yang X, et al. Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2020. PMID: 33097975. doi:10.1007/s00259-020-05070-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。